Abbott Laboratories (ABT) Shares Sold by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. lessened its stake in Abbott Laboratories (NYSE:ABT) by 2.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,980 shares of the healthcare product maker’s stock after selling 1,452 shares during the period. Dana Investment Advisors Inc.’s holdings in Abbott Laboratories were worth $3,904,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. QS Investors LLC grew its holdings in Abbott Laboratories by 1.3% during the 4th quarter. QS Investors LLC now owns 75,306 shares of the healthcare product maker’s stock worth $5,447,000 after acquiring an additional 977 shares during the period. Claybrook Capital LLC grew its holdings in Abbott Laboratories by 3,559.3% during the 4th quarter. Claybrook Capital LLC now owns 58,549 shares of the healthcare product maker’s stock worth $4,235,000 after acquiring an additional 56,949 shares during the period. Abacus Planning Group Inc. grew its holdings in Abbott Laboratories by 1,765.9% during the 4th quarter. Abacus Planning Group Inc. now owns 58,793 shares of the healthcare product maker’s stock worth $9,274,000 after acquiring an additional 55,642 shares during the period. Edmond DE Rothschild Holding S.A. grew its holdings in Abbott Laboratories by 26.9% during the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 206,435 shares of the healthcare product maker’s stock worth $14,932,000 after acquiring an additional 43,704 shares during the period. Finally, PRW Wealth Management LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth $142,000. Hedge funds and other institutional investors own 75.17% of the company’s stock.

In other news, insider Jaime Contreras sold 177,457 shares of the business’s stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $70.00, for a total value of $12,421,990.00. Following the completion of the transaction, the insider now owns 100,985 shares of the company’s stock, valued at approximately $7,068,950. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Brian B. Yoor sold 2,246 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $78.00, for a total transaction of $175,188.00. Following the completion of the transaction, the chief financial officer now directly owns 116,627 shares of the company’s stock, valued at approximately $9,096,906. The disclosure for this sale can be found here. Insiders sold a total of 280,021 shares of company stock valued at $20,485,856 in the last three months. 0.70% of the stock is owned by company insiders.

A number of research firms have commented on ABT. Royal Bank of Canada lifted their target price on shares of Abbott Laboratories to $82.00 and gave the stock a “buy” rating in a report on Monday. They noted that the move was a valuation call. Barclays set a $84.00 target price on shares of Abbott Laboratories and gave the stock a “buy” rating in a report on Friday, March 8th. Argus lifted their target price on shares of Abbott Laboratories to $90.00 and gave the stock an “in-line” rating in a report on Friday, January 25th. They noted that the move was a valuation call. BTIG Research reaffirmed a “hold” rating on shares of Abbott Laboratories in a report on Thursday, January 24th. Finally, Gabelli reaffirmed a “buy” rating on shares of Abbott Laboratories in a report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $80.48.

Shares of ABT stock opened at $76.38 on Wednesday. Abbott Laboratories has a 12-month low of $56.81 and a 12-month high of $80.74. The firm has a market capitalization of $136.13 billion, a PE ratio of 26.91, a PEG ratio of 2.08 and a beta of 1.13. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.62 and a quick ratio of 1.20.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, January 23rd. The healthcare product maker reported $0.81 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.81. Abbott Laboratories had a net margin of 7.74% and a return on equity of 16.55%. The company had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.82 billion. During the same quarter in the previous year, the business earned $0.74 EPS. The firm’s revenue was up 2.3% on a year-over-year basis. Equities analysts expect that Abbott Laboratories will post 3.2 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 1.68%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is 44.44%.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.com-unik.info/2019/04/17/abbott-laboratories-abt-shares-sold-by-dana-investment-advisors-inc.html.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Further Reading: How to Track your Portfolio in Google Finance

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit